Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common Weight-Loss drug shield the brain? early trial launches

NCT ID NCT06171152

Terminated Knowledge-focused Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests whether liraglutide (Saxenda), a weight-loss drug, can raise levels of a brain-protective protein called BDNF in 30 people with multiple sclerosis, long-COVID, or leukemia who are overweight and have memory or concentration problems. Participants will inject liraglutide daily for about 21 weeks while researchers track BDNF levels. The study is currently suspended and is very early-stage, so it aims to gather clues rather than prove a treatment works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
liraglutide (Saxenda)
What this could lead to
If it works, this could point toward a way to protect the brain in people with multiple sclerosis, long-COVID, or leukemia who also struggle with weight and thinking problems.
What could go wrong
This is a very early, small pilot study (30 people) that is currently suspended. It only measures a blood marker (BDNF), not actual cognitive improvement, so even positive results may not lead to a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA IN REMISSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute leukemia long COVID-19 morbid obesity multiple sclerosis Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LEUKEMIA IN REMISSION LONG COVID LONG COVID19 MULTIPLE SCLEROSIS OBESE OBESITY OBESITY, MORBID

Contacts and locations

Locations

  • University of Chicago Medicine Comprehensive Cancer Center

    Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.